Premium
[IC‐01–05]: FIRST‐IN‐HUMAN PET STUDIES WITH THE NEXT GENERATION TAU AGENT 18‐F PI‐2620 IN ALZHEIMER's DISEASE, PROGRESSIVE SUPRANUCLEAR PALSY, AND CONTROLS
Author(s) -
Barret Olivier,
Seibyl John,
Stephens Andrew,
Madonia Jennifer,
Alagille David,
Mueller Andre,
Berndt Mathias,
Kroth Heiko,
Capotosti Francesca,
Muhs Andreas,
Pfeifer Andrea,
Tamagnan Gilles,
Dinkelborg Ludger,
Marek Kenneth
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.2625
Subject(s) - progressive supranuclear palsy , precuneus , corticobasal degeneration , neuroscience , positron emission tomography , chemistry , human brain , tauopathy , pittsburgh compound b , posterior cingulate , pathology , nuclear medicine , medicine , alzheimer's disease , neurodegeneration , psychology , cortex (anatomy) , disease , cognition
correlation between global FMM retention and brain atrophy in any groups. There were positive correlations between THK retention in the frontal, parietal, occipital cortices or precuneus and FMM retention in the frontal, parietal cortices or precuneus. EOAD had weak positive correlation between THK and FMM retention only in the occipital cortex. Conclusions: LOAD showed gradual increase in both tau and amyloid and those two pathologies have association to each other. Whereas, in EOAD, tau and amyloid may develop more abruptly and independently. Brain atrophy was associated with tau burden inEOAD, however,was not correlatedwith amyloid burden in EOAD or LOAD. These findings suggest LOAD and EOAD may have different courses of pathomechanism.